Case report: Olanzapine-induced acute pancreatitis and new diabetes mellitus

Erik Monasterio, Ruchi Bhalla, Andrew McKean

Department of Psychological Medicine, University of Otago, Christchurch, New Zealand.
Hammersmith and Fulham Mental Health Unit, West London Mental Health NHS Trust, London, UK.
Hillmorton Hospital, Christchurch, New Zealand.

DOI: 10.4236/ojpsych.2012.22015                

Abstract

The aim of this case study is to review the literature and report the first published case of olanzapine-induced acute pancreatitis in New Zealand. A case report of acute pancreatitis with new onset diabetes mellitus secondary to olanzapine in a 42-year-old male, in the absence of medical risk factors is reported. Eleven previous case reports of olanzapine induced acute-pancreatitis were identified in the literature. A 42-year-old male was diagnosed with acute pancreatitis and new diabetes mellitus induced by olanzapine. Although rare, pancreatitis is associated with use of some atypical antipsychotic medications. It is important for prescribers to be aware of this potentially fatal side effect. In addition to this, we are highlighting the well documented evidence of metabolic disruption associated with olanzapine.

Keywords

Case Report; Olanzapine; Pancreatitis; Diabetes Mellitus

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Melkersson, K. and Dahl, M. (2004) Adverse metabolic effects associated with atypical antipsychotics: Literature review and clinical implications. Drugs, 64, 701-723. doi:10.2165/00003495-200464070-00003
[2]	Newcomer, J.W. (2005) Second-generation (atypical) antipsychotics and metabolic effects: A comprehensive literature review. CNS Drugs, 19, 1-93.
[3]	ü?ok, A. and Gaebel, W. (2008) Side effects of atypical antipsychotics: A brief overview. World Psychiatry, 7, 58-62.
[4]	Wilson, K. and Bloor, R. (2001) New Zealand pharmaceutical schedule. Pharmaceutical Management Agency, Wellington.
[5]	Anon (2011) Olanzapine funding decisions. PHARMAC notification. www.pharmac.govt.nz
[6]	Collin, A., Clevenot, D., Moulin, P., Macabeo, C. and David, J.S. (2009) Acute pancreatitis induced by olanzapine. Annales fran?aises d’Anesthésie et de Réanimation 28, 907-909. doi:10.1016/j.annfar.2009.09.002
[7]	Kahn, D. and Bourgeois, J.A. (2007) Acute pancreatitis and diabetic ketoacidosis in a schizophrenic patient taking olanzapine. Journal of Clinical Psychopharmacology, 27, 397-400. doi:10.1097/01.jcp.0000264990.93652.80
[8]	Rossor, A.M., Leech, N. and Neely, R.D. (2007) Olanzapine induced chylomicronemia presenting as acute pancreatitis. Journal of Clinical Psychopharmacology, 27, 395-396. doi:10.1097/01.jcp.0000264988.55603.bb
[9]	Waage, C., Carlsson, H. and Nilsen, E.W. (2004) Olanzapine induced pancreatitis: A case report. Journal of the Pancreas, 5, 388-391.
[10]	Hagger, R., Brown, C. and Hurley, P. (2000) Olanzapine and pancreatitis. British Journal of Psychiatry, 177, 567. doi:10.1192/bjp.177.6.567
[11]	Doucette, D.E., Grenier, J.P. and Robertson, P.S. (2000) Olanzapine-induced acute pancreatitis. The Annals of Pharmacotherapy, 34, 128-1131. doi:10.1345/aph.19390
[12]	Belli, H., Sertbas, Y. and Bayik, Y. (2005) Olanzapineinduced diabetes due to pancreatitis. Indian Journal of Gastroenterology, 24, 273.
[13]	Bracamonte, J., Underhill, M. and Sarmiento, P. (2010) Acute pancreatitis associated with lisinopril and olanzapine. American Journal of Health-system Pharmacy, 67, 214-216. doi:10.2146/ajhp080519
[14]	Naranjo, C.A., Busto, U., Sellers, E.M., et al. (1981). A method for estimating the probability of adverse drug reactions. Clinical Pharmacology & Therapeurics, 30, 239-245. doi:10.1038/clpt.1981.154
[15]	Koller, E., Cross, J., Doraiswamy, P. and Malozowski, S. (2003) Pancreatitis associated with atypical antipsychotics: From the food and drug administration’s medwatch surveillance system and published reports. Pharmacotherapy, 23, 1123-1130. doi:10.1592/phco.23.10.1123.32759
[16]	Anon (2011) United Kingdom MHRA olanzapine drug analysis prints. http://www.mhra.govt.uk/Safetyinformation/howwemonitorthesafetyofproducts/Medicines/TheYellowCardScheme/ YellowCarddata/Druganalysisprints/index.htmAccessA
[17]	Koller, E.A. and Doraiswamy, P.M. (2002) Olanzapineinduced diabetes mellitus. Pharmacotherapy, 22, 841-852. doi:10.1592/phco.22.11.841.33629
[18]	Bettinger, T.L., Mendelson, S.C. and Dorson, P.G. and Crimson, M.L. (2000) Olanzapine-induced glucose dysregulation. Annals of Pharmacotherapy, 34, 865-867. doi:10.1345/aph.19327
[19]	Chiu, C., Chen, C., Chen, B., Yu, S. and Mong-Liang, L. (2010) The time-dependent change of insulin secretion in schizophrenic patients treated with olanzapine. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 34, 866-870. doi:10.1016/j.pnpbp.2010.04.003